Shire (NASDAQ:SHPG) – Equities researchers at SunTrust Banks increased their FY2019 earnings per share (EPS) estimates for Shire in a report released on Monday, April 16th. SunTrust Banks analyst J. Boris now anticipates that the biopharmaceutical company will earn $16.03 per share for the year, up from their previous estimate of $15.65. SunTrust Banks currently has a “Buy” rating and a $190.00 target price on the stock. SunTrust Banks also issued estimates for Shire’s FY2020 earnings at $17.28 EPS and FY2022 earnings at $20.22 EPS.
SHPG has been the topic of a number of other reports. Cowen set a $225.00 price target on shares of Shire and gave the stock a “buy” rating in a research note on Friday, January 5th. JPMorgan Chase lowered shares of Shire from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $200.00 to $150.00 in a research note on Monday, February 19th. Zacks Investment Research upgraded shares of Shire from a “sell” rating to a “hold” rating in a research note on Friday, March 23rd. Piper Jaffray reiterated a “hold” rating on shares of Shire in a research note on Wednesday, January 3rd. Finally, Cantor Fitzgerald set a $222.00 price target on shares of Shire and gave the stock a “buy” rating in a research note on Wednesday, December 27th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $204.64.
Shire (NASDAQ:SHPG) last issued its quarterly earnings results on Thursday, April 26th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.58 by ($0.21). Shire had a return on equity of 14.19% and a net margin of 28.17%.
A number of institutional investors have recently made changes to their positions in the business. CNB Bank purchased a new position in Shire in the fourth quarter valued at approximately $349,000. Delek Group Ltd. purchased a new position in Shire in the fourth quarter valued at approximately $19,478,000. Sawtooth Solutions LLC purchased a new position in Shire in the fourth quarter valued at approximately $200,000. Fore Capital LLC purchased a new position in Shire in the fourth quarter valued at approximately $527,000. Finally, APCM Wealth Management for Individuals purchased a new position in Shire in the fourth quarter valued at approximately $491,000. Institutional investors own 19.58% of the company’s stock.
The business also recently declared a semiannual dividend, which will be paid on Tuesday, April 24th. Shareholders of record on Friday, March 9th will be paid a $0.8937 dividend. This is a positive change from Shire’s previous semiannual dividend of $0.15. This represents a yield of 1.33%. The ex-dividend date is Thursday, March 8th. Shire’s dividend payout ratio is currently 6.93%.
WARNING: “SunTrust Banks Analysts Increase Earnings Estimates for Shire (SHPG)” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://weekherald.com/2018/04/20/suntrust-banks-analysts-increase-earnings-estimates-for-shire-shpg.html.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.